Apr 30, 2020
PTC Therapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update
Feb 03, 2020
PTC Therapeutics Announces First Publication of Real-World Data Showing Translarnaä (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy
Jan 13, 2020
PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference
Oct 04, 2019
PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
Jun 28, 2019
PTC Provides Update on Translarna(TM) (ataluren) Application for Label Expansion
Apr 29, 2019
Translarna(TM) (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy
Jan 07, 2019
PTC Therapeutics Provides Corporate Update and Outlines 5-year Strategic Plan at 2019 J.P. Morgan Healthcare Conference
Dec 18, 2018
PTC Therapeutics Deepens Financial and Commercial Expertise of Board with Two New Appointments
Nov 05, 2018
PTC Therapeutics Reports Third Quarter 2018 Financial Results and Provides a Corporate Update
Oct 06, 2018
PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation
Aug 23, 2018
PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics
Jul 24, 2018
PTC Therapeutics Announces Publication of Data Demonstrating the Clinical Differentiated Benefit of Deflazacort
Jul 09, 2018
PTC Therapeutics Announces Positive Data from its Translarna(TM) Phase II Clinical Trial in Children as Young as Two Years with Nonsense Mutation Duchenne Muscular Dystrophy
Jun 25, 2018
Global Cystic Fibrosis Industry
May 09, 2018
PTC Therapeutics Reports First Quarter 2018 Financial Results and Provides a Corporate Update
Feb 20, 2018
PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA's Office of New Drugs
Jan 08, 2018
PTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities
Nov 02, 2017
PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Oct 25, 2017
PTC Therapeutics Receives Complete Response Letter for Ataluren's NDA
Aug 08, 2017
PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update